Predictive Oncology Inc
POAI0.795USD
+0.033+4.33%
Market hours （ET）Quotes delayed by 15 min
7.10MMarket Cap
LossP/E TTM
More Details of Predictive Oncology Inc Company
Predictive Oncology Inc. is a knowledge-driven company focused on applying artificial intelligence (AI) to support the development of cancer therapies. The Company operates through three segments: Pittsburgh, Birmingham, and Eagan. Pittsburgh segment provides services, which include the application of artificial intelligence (AI) using its proprietary biobank of 150,000 plus tumor samples. Pittsburgh segment also develops tumor-specific in vitro models for oncology drug discovery and research. Birmingham segment focuses on contract services and research for biopharmaceutical company clients and academic collaborators, focused on solubility improvements, stability studies, and protein production. Specifically, Birmingham provides optimized formulations for vaccines, antibodies, and other protein therapeutics. Eagan segment produces the STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal.
Company Info
Ticker SymbolPOAI
Company namePredictive Oncology Inc
IPO dateDec 18, 2009
CEOMr. Raymond F. Vennare
Number of employees23
Security typeOrdinary Share
Fiscal year-endDec 18
Address91 43Rd Street
CityPITTSBURGH
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code15201
Phone14124321500
Websitehttps://predictive-oncology.com/
Ticker SymbolPOAI
IPO dateDec 18, 2009
CEOMr. Raymond F. Vennare
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Nancy Chung-Welch, Ph.D.
Dr. Nancy Chung-Welch, Ph.D.
Independent Director
Independent Director
19.31K
+11.64%
Dr. Daniel E. (Dan) Handley, Ph.D.
Dr. Daniel E. (Dan) Handley, Ph.D.
Independent Director
Independent Director
17.02K
+10.69%
Dr. Veena Rao, Ph.D.
Dr. Veena Rao, Ph.D.
Independent Director
Independent Director
9.12K
--
Mr. Raymond F. Vennare
Mr. Raymond F. Vennare
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
7.12K
--
Dr. Matthew J. Hawryluk, Ph.D.
Dr. Matthew J. Hawryluk, Ph.D.
Independent Director
Independent Director
--
--
Mr. Gregory S. St. Clair, Sr.
Mr. Gregory S. St. Clair, Sr.
Independent Director
Independent Director
--
--
Mr. Joshua Blacher
Mr. Joshua Blacher
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Mr. Chuck (Charles) Nuzum, Sr.
Mr. Chuck (Charles) Nuzum, Sr.
Lead Independent Director
Lead Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Nancy Chung-Welch, Ph.D.
Dr. Nancy Chung-Welch, Ph.D.
Independent Director
Independent Director
19.31K
+11.64%
Dr. Daniel E. (Dan) Handley, Ph.D.
Dr. Daniel E. (Dan) Handley, Ph.D.
Independent Director
Independent Director
17.02K
+10.69%
Dr. Veena Rao, Ph.D.
Dr. Veena Rao, Ph.D.
Independent Director
Independent Director
9.12K
--
Mr. Raymond F. Vennare
Mr. Raymond F. Vennare
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
7.12K
--
Dr. Matthew J. Hawryluk, Ph.D.
Dr. Matthew J. Hawryluk, Ph.D.
Independent Director
Independent Director
--
--
Mr. Gregory S. St. Clair, Sr.
Mr. Gregory S. St. Clair, Sr.
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Tue, Jul 15
Updated: Tue, Jul 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
0.70%
Geode Capital Management, L.L.C.
0.62%
Nuzum (Charles Lee Sr)
0.29%
St Clair (Gregory Sr)
0.21%
Chung-Welch (Nancy)
0.19%
Other
98.00%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
0.70%
Geode Capital Management, L.L.C.
0.62%
Nuzum (Charles Lee Sr)
0.29%
St Clair (Gregory Sr)
0.21%
Chung-Welch (Nancy)
0.19%
Other
98.00%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
1.56%
Individual Investor
1.18%
Investment Advisor
0.21%
Endowment Fund
0.11%
Hedge Fund
0.05%
Research Firm
0.01%
Other
96.89%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
44
299.26K
2.93%
-277.17K
2025Q1
50
299.35K
3.35%
-293.31K
2024Q4
56
353.94K
4.97%
-213.96K
2024Q3
54
322.08K
5.97%
-246.26K
2024Q2
57
408.73K
8.00%
-114.07K
2024Q1
66
484.20K
11.91%
-86.59K
2023Q4
66
502.45K
12.36%
-67.11K
2023Q3
69
499.46K
12.41%
-50.95K
2023Q2
67
353.15K
8.84%
-144.84K
2023Q1
72
429.97K
10.87%
-298.57K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
71.31K
0.8%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
62.93K
0.7%
+11.72K
+22.90%
Mar 31, 2025
Nuzum (Charles Lee Sr)
29.91K
0.33%
+2.01K
+7.22%
Mar 20, 2025
St Clair (Gregory Sr)
21.20K
0.24%
+1.33K
+6.70%
Mar 20, 2025
Chung-Welch (Nancy)
19.31K
0.22%
+2.01K
+11.64%
Mar 20, 2025
UBS Financial Services, Inc.
18.98K
0.21%
+18.98K
--
Mar 31, 2025
Handley (Daniel E)
17.02K
0.19%
+1.64K
+10.69%
Mar 20, 2025
State Street Global Advisors (US)
13.84K
0.15%
--
--
Mar 31, 2025
Carnegie Mellon University
10.36K
0.12%
--
--
Mar 31, 2025
Hawryluk (Matthew)
9.49K
0.11%
--
--
Mar 20, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Apr 20, 2023
Merger
20<1
Apr 20, 2023
Merger
20<1
Apr 20, 2023
Merger
20<1
Apr 20, 2023
Merger
20<1
Date
Type
Ratio
Apr 20, 2023
Merger
20<1
Apr 20, 2023
Merger
20<1
Apr 20, 2023
Merger
20<1
Apr 20, 2023
Merger
20<1
